Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - protamine crystallised insulin asparte; soluble insulin asparte -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin aspart -

Israel - English - Ministry of Health

novo nordisk ltd., israel - glucagon as hydrochloride - powder and solvent for solution for injection - glucagon as hydrochloride 1 mg - glucagon - glucagon - treatment of severe hypoglycaemia reactions which may occur in the management of insulin treated persons with diabetes.

Israel - English - Ministry of Health

novo nordisk ltd., israel - estradiol hemihydrate - film coated tablets - estradiol hemihydrate 10 mcg - estradiol - estradiol - treatment of atrophic vaginitis due to estrogen deficiency in postmenopausal women.the experience treating women older than 65 years is limited.שינוי משטר מינון: 1/7/2019שינויים בעלון לרופא בסעיף posology:4.2 posology and method of administrationvagifem is administered intravaginally as a local oestrogen therapy by use of an applicator. initial dose: one vaginal tablet daily for two weeks. maintenance dose: one vaginal tablet twice a week.treatment may be started on any convenient day.if a dose is forgotten, it should be taken as soon as the patient remembers. a double dose should be avoided.for initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration (see also section 4.4) should be used.for oestrogen products for vaginal application of which the systemic exposure to the oestrogen remains within the normal postmenopausal range, such as vagifem, it is not recommended to add a progestagen (but see section 4.4, ‘special warnings and precautions for use’, ‘endometrial hyperplasia and carcinoma’).

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - catridecacog, quantity: 5.25 mg/ml - drug delivery system - excipient ingredients: - novothirteen is indicated for routine prophylaxis of bleeding in patients with congenital factor xiii a-subunit deficiency.

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - protamine-crystallised insulin aspart; soluble insulin aspart - injection - 70.00% - protamine-crystallised insulin aspart 70%; soluble insulin aspart 30%

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - eptacog alfa (activated)/rfviia - injection, powder, for solution - 1mg - eptacog alfa (activated)/rfviia 1mg

Singapore - English - HSA (Health Sciences Authority)

novo nordisk pharma (singapore) pte ltd - eptacog alfa (activated)/rfviia - injection, powder, for solution - 2mg - eptacog alfa (activated)/rfviia 2mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin aspart -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - insulin aspart -